BUREAU VERITAS: Number of shares and voting rights as of February 28, 2026 REGULATED INFORMATION Courbevoie, France – March 6, 2026 Information on number of shares and voting rights as provided by article 223-16 of the general regulations of the French financial markets authority AMF Issuer: Bureau Veritas DateNumber of shares (1)Number of voting rights28/02/2026453,900,202Theoretical number of voting rights: 560,823,062Number of exercisable voting rights: 550,633,982 (1) including the new shares issued in Euroclear as a result of the exercise of stock options since January 1, 2026, if ...
BUREAU VERITAS : Nombre d'actions et de droits de vote au 28 février 2026 INFORMATION RÈGLEMENTÉE Courbevoie, France – 6 mars 2026 Information relative au nombre d’actions et de droits de vote prévue par l’article 223-16 du règlement général de l’Autorité des marchés financiers Emetteur : Bureau Veritas Date de l’arrêtéNombre d’actions en circulation (1)Nombre total de droits de vote28/02/2026453 900 202Nombre de droits de vote théoriques : 560 823 062Nombre de droits de vote exerçables : 550 633 982 (1) y compris les actions nouvelles créées en Euroclear du fait des levées d’options ...
2025 marked a turning point for Cellnex as its Free Cash Flow generation accelerated. Moreover, the company continues to reduce leverage, through growth and divestments, to meet its leverage target of 5.0-6.0x net debt to EBITDA. We continue to believe the notes look attractive.
4Q'25 vs. 4Q'24 Results Sales: € 1.058 Bn (+1.9% vs. -1.4% BS(e) and +1.0% consensus); EBITDA: € 881.0 M (+2.1% vs. +0.1% BS(e) and +1.0% consensus); FY2025 vs. FY2024 Results Sales: € 3.995 Bn (+1.4% vs. +0.5% BS(e) and +1.1% consensus); EBITDA: € 3.317 Bn (+2.1% vs. +1.5% BS(e) and +1.8% consensus); Net Profit: € -361.0 M (€ -28.0 M in FY2024);
INEOS Quattro: conference call comments|NIH: improvement in certain indicators in H2, but still little visibility on M&A|Ardagh Group surprises with strong increase in glass EBITDA in Q4|Clariane : Satisfactory 2025 results thanks to strong recovery in H2 25 and B2/B+ ratings assigned by Moody’s and S&P|
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.